1
|
Yun TH, Kim MJ, Lee JG, Bang KH, Kim KS. Enhanced Stability and Compatibility of Montelukast and Levocetirizine in a Fixed-Dose Combination Monolayer Tablet. Pharmaceutics 2024; 16:963. [PMID: 39065660 PMCID: PMC11279677 DOI: 10.3390/pharmaceutics16070963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2024] [Revised: 07/16/2024] [Accepted: 07/19/2024] [Indexed: 07/28/2024] Open
Abstract
The purpose of this study was to enhance the stability of montelukast and levocetirizine for the development of a fixed-dose combination (FDC) monolayer tablet. To evaluate the compatibility of montelukast and levocetirizine, a mixture of the two drugs was prepared, and changes in the appearance characteristics and impurity content were observed in a dry oven at 60 °C. Excipients that contributed minimally to impurity increases were selected to minimize drug interactions. Mannitol, microcrystalline cellulose, croscarmellose sodium, hypromellose, and sodium citrate were chosen as excipients, and montelukast-levocetirizine FDC monolayer tablets were prepared by wet granulating the two drugs separately. A separate granulation of montelukast and levocetirizine, along with the addition of sodium citrate as a pH stabilizer, minimized the changes in tablet appearance and impurity levels. The prepared tablets demonstrated release profiles equivalent to those of commercial products in comparative dissolution tests. Subsequent stability testing at 40 ± 2 °C and 75 ± 5% RH for 6 months confirmed that the drug content, dissolution rate, and impurity content met the specified acceptance criteria. In conclusion, the montelukast-levocetirizine FDC monolayer tablet developed in this study offers a potential alternative to commercial products.
Collapse
Affiliation(s)
| | | | | | | | - Kyeong Soo Kim
- Department of Pharmaceutical Engineering, Gyeongsang National University, 33 Dongjin-ro, Jinju 52725, Republic of Korea; (T.H.Y.); (M.J.K.); (J.G.L.); (K.H.B.)
| |
Collapse
|
2
|
Sharma P, Tailang M. Primaquine-loaded transdermal patch for treating malaria: design, development, and characterization. FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES 2022. [DOI: 10.1186/s43094-022-00433-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
The goal of the current study was to create, improve, and test a transdermal patch loaded with primaquine for the treatment of malaria. Several ingredients were used to create the transdermal patch. For the choosing of polymers, placebo patches were created. The optimization of polymer ratios for patch development and testing their impact on tensile strength, in vitro drug release, in vitro drug permeation, and ex vivo drug permeation employed response surface methods. The F5 formulation was chosen as the optimal formulation based on these answers to the data. The stability of the F5 formulation was examined. According to the findings of trials on acute skin irritation, no place where transdermal patches were given showed any signs of clinical abnormalities or a change in body weight. No erythema or edema of the skin was seen in the rabbit’s skin.
Results
It was observed that tensile strength of the transdermal films formulated with Eudragit RL100 and hydroxypropyl methylcellulose (Pmix) was found between 0.32 ± 0.017 and 0.59 ± 0.013 kg/cm2, which were 0.32 ± 0.017 (F1), 0.36 ± 0.012 (F2), 0.35 ± 0.015 (F3) for Pmix ratio 1:1, 0.42 ± 0.011 (F4), 0.49 ± 0.010 (F5), 0.55 ± 0.016 (F6) for Pmix ratio 1:2 and 0.56 ± 0.014 (F7), 0.57 ± 0.010 (F8), 0.59 ± 0.013 (F9) for Pmix ratio 1:3. Data fitting to the Peppas, Hixon–Crowell, Higuchi, and Zero-order models was used to examine the optimized transdermal patch (F5) release kinetic mechanism. Data comparison was done using the correlation coefficient (R2). Zero-order had an observed correlation coefficient (R2) of 0.9988, which was greater than that for other models. Therefore, it was clear that the medication was released from the formulation after the Zero-order release.
Conclusion
The ideal thickness, percent elongation, and tensile strength of the primaquine therapeutic transdermal patches were prepared for transdermal delivery. The therapeutic transdermal patch was prepared by using Eudragit RL100: HPMC K15M (1:2) into the patch because this combination was responsible for the significant delivery of the drug into the bloodstream. The therapeutic transdermal patch has a notable penetration rate. Dimethyl sulfoxide was used as a permeation enhancer, which helped to obtain a high penetration rate. The statistical analysis was used to support the improved formulation. The therapeutic transdermal patch is a potential vehicle for the administration of primaquine, according to stability studies.
Collapse
|
3
|
Evaluation of the Compatibility of Moxifloxacin with Selected Excipients Used in the Formulation of Nanopharmaceuticals. Pharm Chem J 2022. [DOI: 10.1007/s11094-022-02556-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
4
|
Kolisnyk T, Vashchenko O, Ruban O, Fil N, Slipchenko G. Assessing compatibility of excipients selected for a sustained release formulation of bilberry leaf extract. BRAZ J PHARM SCI 2022. [DOI: 10.1590/s2175-97902022e19753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
| | - Olga Vashchenko
- Institute for Scintillation Materials of NAS of Ukraine, Ukraine
| | | | - Nataliya Fil
- Kharkiv National Automobile and Highway University, Ukraine
| | | |
Collapse
|
5
|
Aminu N, Chan SY, Mumuni MA, Umar NM, Tanko N, Zauro SA, Aminu A, Toh SM. Physicochemical compatibility studies of triclosan and flurbiprofen with excipients of pharmaceutical formulation using binary, ternary, and multi-combination approach. FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES 2021. [DOI: 10.1186/s43094-021-00302-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Abstract
Background
The aim of the study was to evaluate the suitability of triclosan (TCS) and flurbiprofen (FLB) with poly-ε-caprolactone (PCL), chitosan (CS), and Kolliphor® P188 (KP) for possible application in the design of nano-formulations.
Results
Differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), and scanning electron microscopy (SEM) revealed the physical characteristics of the various sample compositions without any apparent interaction. The Fourier transform infrared spectroscopy (FTIR)’s spectra of the physical mixtures showed their characteristic absorption bands with broadening and overlapping of bands in some instances, but no appearance of new bands was observed.
Conclusion
The study revealed the physical form stability of the evaluated components after the storage period and lack of definite pharmaceutical incompatibility between them. Thus, the selected drugs and excipients could be used for the development of pharmaceutical nano-formulations.
Collapse
|
6
|
Veiga A, Stofella NCF, Oliveira LJ, Montin EF, Bauab T, Malucelli LC, Filho MASC, Oliveira PR, Murakami FS. Thermal Analytical Approaches to Characterization and Compatibility Studies of Duloxetine Hydrochloride. Pharm Chem J 2020. [DOI: 10.1007/s11094-020-02249-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
7
|
Physicochemical Compatibility Investigation of Mesalazine and Folic Acid Using Chromatographic and Thermoanalytical Techniques. Pharmaceuticals (Basel) 2020; 13:ph13080187. [PMID: 32784456 PMCID: PMC7463986 DOI: 10.3390/ph13080187] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Revised: 08/05/2020] [Accepted: 08/07/2020] [Indexed: 01/18/2023] Open
Abstract
Inflammatory bowel disease is a common name for Crohn’s disease and ulcerative colitis. These inflammatory states cause damage in the sidewalls of the gastrointestinal tract, resulting in malabsorption of food and vitamins. Folic acid (Vitamin B9) is often associated with inflammatory bowel diseases since reduced overall folate concentration in the human body may lead to the development of colorectal cancer and megaloblastic anaemia. However, its deficiency is easily compensated by taking an additional folic acid pill during regular therapy. At the moment, there are no studies that have examined the compatibility of folic acid with 5-aminosalicylate drugs used in the treatment of inflammatory bowel diseases. In this work, differential scanning calorimetry, forced degradation studies, isothermal stress testing and dissolution stability testing were used to determine the stability of folic acid and one of the most commonly used 5-aminosalicylates, mesalazine, when present in the same solution or blend. To monitor the assay of folic acid, mesalazine and nine of its related impurities, a single HPLC method was developed. Results of compatibility studies showed that no physicochemical interaction between mesalazine and folic acid occurs when combined, opening the path to the development of new formulations, such as a mesalazine/folic acid fixed-dose combination.
Collapse
|
8
|
Kalaria DR, Parker K, Reynolds GK, Laru J. An industrial approach towards solid dosage development for first-in-human studies: Application of predictive science and lean principles. Drug Discov Today 2020; 25:505-518. [DOI: 10.1016/j.drudis.2019.12.012] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 12/16/2019] [Accepted: 12/30/2019] [Indexed: 01/24/2023]
|
9
|
Influence of different viscosity grade cellulose-based polymers on the development of valsartan controlled release tablets. Polym Bull (Berl) 2020. [DOI: 10.1007/s00289-019-02802-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Review of the physicochemical methods applied in the investigation of the maillard reaction in pharmaceutical preparations. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2019.101362] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
11
|
Niguram P, Polaka SN, Rathod R, Kalia K, Kate AS. Update on compatibility assessment of empagliflozin with the selected pharmaceutical excipients employed in solid dosage forms by thermal, spectroscopic and chromatographic techniques. Drug Dev Ind Pharm 2020; 46:209-218. [PMID: 31933394 DOI: 10.1080/03639045.2020.1716371] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Empagliflozin (EGF) received USFDA approval in 2014 for oral use to control the glucose levels in adults with type 2 diabetes mellitus. Albeit, a systematic drug-excipient compatibility study of EGF has not been reported in the open literature. As physical and chemical interactions affect the performance of the formulation, this study intended to unveil the drug and excipients interactions which would later help in development of a robust solid dosage form. Differential scanning calorimetry (DSC) was applied as a screening tool for the assessment of compatibility between EGF and the list of excipients mentioned in the EMEA summary of product characteristics (SmPC)-section 6.1, along with mannitol and polyvinylpyrrolidone. Thermogravimetric analysis (TGA), Fourier Transform Infrared Spectroscopy (FTIR), X-ray Powder Diffraction (PXRD) and Hot Stage Microscopy (HSM) methods were utilized to appraise the interpretation of DSC results adequately. Isothermal stress testing (IST) studies of EGF were performed using the selected excipients to check the presence of interaction products (IPs) and the drug content by HPLC. Additional peaks were observed in the EGF-macrogol mixture than the drug peak in the HPLC analysis after two and half months, and those were separated and identified by the Ultra-High Performance Liquid Chromatography-Quadrupole Time of Flight Mass Spectrometry (UHPLC-QTOF-MS). Overall, EGF had shown compatibility with 13 selected excipients; however, initial observation of DSC and IST studies indicated plausible interaction of the EGF with macrogol.
Collapse
Affiliation(s)
- Prakash Niguram
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad, Gandhinagar, India
| | - Surya Narayana Polaka
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad, Gandhinagar, India
| | - Rajeshwari Rathod
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad, Gandhinagar, India
| | - Kiran Kalia
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad, Gandhinagar, India
| | - Abhijeet S Kate
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad, Gandhinagar, India.,Department of Natural Products, National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad, Gandhinagar, India
| |
Collapse
|
12
|
Khan A. Optimization of the process variables of roller compaction, on the basis of granules characteristics (flow, mechanical strength, and disintegration behavior): an application of SeDeM-ODT expert system. Drug Dev Ind Pharm 2019; 45:1537-1546. [PMID: 31210544 DOI: 10.1080/03639045.2019.1634094] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The objective of the study was application of SeDeM-ODT expert system for optimization of process variables for roller compaction and for the preparation of granules with better flow, compressibility, and disintegration behavior. In the present study, granules were prepared at pre-determined (on the basis of factorial design) process variables and characterized using SeDeM-ODT expert system. Compatibility of ribavirin with excipients (microcrystalline cellulose, tablettose-80, cross carmellose sodium, and magnesium stearate) was evaluated by binary mixture approach, using FTIR. According to the SeDeM-ODT expert system, granules were characterized for various parameters related to flow, compressibility and disintegration behavior and Index of Good Compressibility and Buccodispersibility (IGCB) was calculated. The process variables resulting in highest IGCB value were considered as optimum. Ribavirin was found compatible with all the excipients used in the study and characteristics peaks were present in FTIR spectra after subjecting to stress conditions (75% relative humidity at 45 ± 5 °C) for 30 days. Both Ribavirin powder and Ribavirin containing powder blend had poor flow and compressibility while disintegration behavior was good due to higher water solubility. Screw speed of 35 rpm and roller speed at 12 rpm resulted in granules with acceptable characteristics. The IGCB value (5.63) of the granules was highest of all, indicating its better characteristics. SeDeM-ODT expert system presents a more practical picture of the granules and also predicts the mechanical strength and disintegration behavior of the tablets prepared from the granules. By proper optimization of screw and roller speed, efficiency of the process can be improved.
Collapse
Affiliation(s)
- Amjad Khan
- a Department of Pharmacy , Kohat University of Science and Technology , Kohat , Pakistan
| |
Collapse
|
13
|
Almeida L, Oshiro Júnior JA, Silva M, Nóbrega F, Andrade J, Santos W, Ribeiro A, Conceição M, Veras G, Medeiros AC. Tablet of Ximenia Americana L. Developed from Mucoadhesive Polymers for Future Use in Oral Treatment of Fungal Infections. Polymers (Basel) 2019; 11:E379. [PMID: 30960363 PMCID: PMC6419192 DOI: 10.3390/polym11020379] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Revised: 02/15/2019] [Accepted: 02/17/2019] [Indexed: 12/14/2022] Open
Abstract
The use of biocompatible polymers such as Hydroxypropylmethylcellulose (HPMC), Hydroxyethylcellulose (HEC), Carboxymethylcellulose (CMC), and Carbopol in solid formulations results in mucoadhesive systems capable of promoting the prolonged and localized release of Active Pharmaceutical Ingredients (APIs). This strategy represents a technological innovation that can be applied to improving the treatment of oral infections, such as oral candidiasis. Therefore, the aim of this study was to develop a tablet of Ximenia americana L. from mucoadhesive polymers for use in the treatment of oral candidiasis. An X. americana extract (MIC of 125 μg·mL-1) was obtained by turbolysis at 50% of ethanol, a level that demonstrated activity against Candida albicans. Differential Thermal Analysis and Fourier Transform Infrared Spectroscopy techniques allowed the choice of HPMC as a mucoadhesive agent, besides polyvinylpyrrolidone, magnesium stearate, and mannitol to integrate the formulation of X. americana. These excipients were granulated with an ethanolic solution 70% v/v at PVP 5%, and a mucoadhesive tablet was obtained by compression. Finally, mucoadhesive strength was evaluated, and the results demonstrated good mucoadhesive forces in mucin disk and pig buccal mucosa. Therefore, the study allowed a new alternative to be developed for the treatment of buccal candidiasis, one which overcomes the inconveniences of common treatments, costs little, and facilitates patients' adhesion.
Collapse
Affiliation(s)
- Lucas Almeida
- Laboratório de Desenvolvimento e Ensaios de Medicamentos, Centro de Ciências Biológicas e da Saúde, Universidade Estadual da Paraíba, R. Baraúnas, 351, Cidade Universitária, 58429-500, Campina Grande, Paraíba, Brasil.
| | - João Augusto Oshiro Júnior
- Laboratório de Desenvolvimento e Ensaios de Medicamentos, Centro de Ciências Biológicas e da Saúde, Universidade Estadual da Paraíba, R. Baraúnas, 351, Cidade Universitária, 58429-500, Campina Grande, Paraíba, Brasil.
| | - Milena Silva
- Laboratório de Desenvolvimento e Ensaios de Medicamentos, Centro de Ciências Biológicas e da Saúde, Universidade Estadual da Paraíba, R. Baraúnas, 351, Cidade Universitária, 58429-500, Campina Grande, Paraíba, Brasil.
| | - Fernanda Nóbrega
- Laboratório de Desenvolvimento e Ensaios de Medicamentos, Centro de Ciências Biológicas e da Saúde, Universidade Estadual da Paraíba, R. Baraúnas, 351, Cidade Universitária, 58429-500, Campina Grande, Paraíba, Brasil.
| | - Jéssica Andrade
- Laboratório de Desenvolvimento e Ensaios de Medicamentos, Centro de Ciências Biológicas e da Saúde, Universidade Estadual da Paraíba, R. Baraúnas, 351, Cidade Universitária, 58429-500, Campina Grande, Paraíba, Brasil.
| | - Widson Santos
- Laboratório de Desenvolvimento e Ensaios de Medicamentos, Centro de Ciências Biológicas e da Saúde, Universidade Estadual da Paraíba, R. Baraúnas, 351, Cidade Universitária, 58429-500, Campina Grande, Paraíba, Brasil.
| | - Angélica Ribeiro
- Laboratório de Desenvolvimento e Ensaios de Medicamentos, Centro de Ciências Biológicas e da Saúde, Universidade Estadual da Paraíba, R. Baraúnas, 351, Cidade Universitária, 58429-500, Campina Grande, Paraíba, Brasil.
| | - Marta Conceição
- Centro de Tecnologia e Desenvolvimento Regional, Universidade Federal da Paraíba, Av. dos Escoteiros, s/n, Mangabeira VII, 58055-000, João Pessoa, Paraíba, Brasil.
| | - Germano Veras
- Laboratório de Química Analítica e Quimiometria, Centro de Ciências Biológicas e da Saúde, Universidade Estadual da Paraíba, R. Baraúnas, 351, Cidade Universitária, 58429-500, Campina Grande, Paraíba, Brasil.
| | - Ana Cláudia Medeiros
- Laboratório de Desenvolvimento e Ensaios de Medicamentos, Centro de Ciências Biológicas e da Saúde, Universidade Estadual da Paraíba, R. Baraúnas, 351, Cidade Universitária, 58429-500, Campina Grande, Paraíba, Brasil.
| |
Collapse
|
14
|
Solid dispersion of praziquantel enhanced solubility and improve the efficacy of the schistosomiasis treatment. J Drug Deliv Sci Technol 2018. [DOI: 10.1016/j.jddst.2018.03.009] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
15
|
Martins SM, Müller V, Galan V, Souza FPD, Andreazza IF, Rosa MFD. Development and evaluation of multiparticulate biphasic system for the treatment of circadian diseases. BRAZ J PHARM SCI 2018. [DOI: 10.1590/s2175-97902018000417167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023] Open
|
16
|
Gao L, Xie C, Du Y, Wang X, Xuan E, Liu X, Zhao Y, Xu J, Luo L. Characterization and antitumor efficacy of poly(L-lactid acid)-based etoposide-loaded implants. Drug Deliv 2017; 24:765-774. [PMID: 28475414 PMCID: PMC8241189 DOI: 10.1080/10717544.2017.1321063] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Etoposide is widely used in the chemotherapy of a variety of malignancies. But the strong lipophilicity, poor bioavailability, and severe side effects of etoposide limit its clinical application. The aim of this study was to develop sustained-release etoposide-loaded implants and evaluate antitumor activity of the implants after intratumoral implantation. We prepared the implants containing etoposide, poly(L-lactid acid) and polyethylene glycol 4000 by the direct compression method. The implants were characterized regarding drug-excipient compatibility, content uniformity, morphology, sterility, in vitro, and in vivo release profiles. Then the antitumor activity of the implants was tested in xenograft model of A549 human non-small cell lung cancer. SEM images displayed smooth surface of the implant and indicated that etoposide was homogeneously dispersed in the polymeric matrix. The results of content uniformity met the requirements of the Chinese Pharmacopoeia. Both in vitro and in vivo release profiles of the implants were characterized by high burst release followed by sustained release of etoposide. Intratumoral implantation of etoposide-loaded implants could efficiently delay the tumor growth. Furthermore, increasing the dose of implants led to higher tumor suppression rate without adding systemic toxicity. These results indicated that etoposide-loaded implants have significant antitumor efficacy in xenograft model without dose-limiting side effects and they possess a strong potential to be used as an intratumoral chemotherapy option for lung cancer treatment.
Collapse
Affiliation(s)
- Li Gao
- a State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University , Nanjing , People's Republic of China.,b School of Biological and Medical Engineering, Hefei University of Technology , Hefei , People's Republic of China
| | - Chuanqi Xie
- c Laboratory of pharmaceutical research , Anhui Zhongren Science and Technology Co., Ltd , Hefei , People's Republic of China , and
| | - Yuzhi Du
- b School of Biological and Medical Engineering, Hefei University of Technology , Hefei , People's Republic of China
| | - Xiaodong Wang
- c Laboratory of pharmaceutical research , Anhui Zhongren Science and Technology Co., Ltd , Hefei , People's Republic of China , and
| | - Erkang Xuan
- c Laboratory of pharmaceutical research , Anhui Zhongren Science and Technology Co., Ltd , Hefei , People's Republic of China , and
| | - Xiuxiu Liu
- b School of Biological and Medical Engineering, Hefei University of Technology , Hefei , People's Republic of China
| | - Yang Zhao
- d Department of Pathology , The Second People's Hospital of Hefei , Hefei , People's Republic of China
| | - Jianjian Xu
- b School of Biological and Medical Engineering, Hefei University of Technology , Hefei , People's Republic of China
| | - Lan Luo
- a State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University , Nanjing , People's Republic of China
| |
Collapse
|
17
|
Ghaderi F, Nemati M, Siahi-Shadbad MR, Valizadeh H, Monajjemzadeh F. Physicochemical evaluation and non-isothermal kinetic study of the drug–excipient interaction between doxepin and lactose. POWDER TECHNOL 2015. [DOI: 10.1016/j.powtec.2015.09.007] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Marothu V, Yerramothu P, Gorrepati M, Majeti S, Mamidala S, Nellutla A. Application of HPLC to assess the compatibility of bisoprolol fumarate with selected excipients in mixtures by isothermal stress testing. ANNALES PHARMACEUTIQUES FRANÇAISES 2015; 73:442-51. [DOI: 10.1016/j.pharma.2015.05.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Revised: 05/18/2015] [Accepted: 05/20/2015] [Indexed: 10/23/2022]
|
19
|
Ramachandran V, Murnane D, Hammond RB, Pickering J, Roberts KJ, Soufian M, Forbes B, Jaffari S, Martin GP, Collins E, Pencheva K. Formulation Pre-screening of Inhalation Powders Using Computational Atom–Atom Systematic Search Method. Mol Pharm 2014; 12:18-33. [DOI: 10.1021/mp500335w] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Vasuki Ramachandran
- Institute
of Particle Science and Engineering, Institute of Process Research
and Development, School of Chemical and Process Engineering, University of Leeds, Leeds LS2 9JT, U.K
| | - Darragh Murnane
- School
of Life and Medical Sciences, University of Hertfordshire, Hertfordshire AL10 9AB, U.K
| | - Robert B. Hammond
- Institute
of Particle Science and Engineering, Institute of Process Research
and Development, School of Chemical and Process Engineering, University of Leeds, Leeds LS2 9JT, U.K
| | - Jonathan Pickering
- Institute
of Particle Science and Engineering, Institute of Process Research
and Development, School of Chemical and Process Engineering, University of Leeds, Leeds LS2 9JT, U.K
| | - Kevin J. Roberts
- Institute
of Particle Science and Engineering, Institute of Process Research
and Development, School of Chemical and Process Engineering, University of Leeds, Leeds LS2 9JT, U.K
| | - Majeed Soufian
- Institute
of Particle Science and Engineering, Institute of Process Research
and Development, School of Chemical and Process Engineering, University of Leeds, Leeds LS2 9JT, U.K
| | - Ben Forbes
- Institute
of Pharmaceutical Sciences, King’s College, London SE1 9NH, U.K
| | - Sara Jaffari
- Institute
of Pharmaceutical Sciences, King’s College, London SE1 9NH, U.K
| | - Gary P. Martin
- Institute
of Pharmaceutical Sciences, King’s College, London SE1 9NH, U.K
| | | | | |
Collapse
|
20
|
Preparation and characterization of liquisolid compacts for improved dissolution of telmisartan. JOURNAL OF DRUG DELIVERY 2014; 2014:692793. [PMID: 25371826 PMCID: PMC4211305 DOI: 10.1155/2014/692793] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Revised: 09/22/2014] [Accepted: 09/22/2014] [Indexed: 11/18/2022]
Abstract
The objective of the present work was to obtain pH independent and improved dissolution profile for a poorly soluble drug, telmisartan using liquisolid compacts. Liquisolid compacts were prepared using Transcutol HP as vehicle, Avicel PH102 as carrier, and Aerosil 200 as a coating material. The formulations were evaluated for drug excipient interactions, change in crystallinity of drug, flow properties, and general quality control tests of tablets using Fourier transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), X-ray diffraction (XRD), angle of repose, and various pharmacopoeial tests. In vitro dissolution studies were performed at three pH conditions (1.2, 4.5 and 7.4). Stability studies were performed at 40°C and 75% RH for three months. The formulation was found to comply with Indian pharmacopoeial limits for tablets. FTIR studies confirmed no interaction between drug and excipients. XRD and DSC studies indicate change/reduction in crystallinity of drug. Dissolution media were selected based on the solubility studies. The optimized formulation showed pH independent release profile with significant improvement (P < 0.005) in dissolution compared to plain drug and conventional marketed formulation. No significant difference was seen in the tablet properties, and drug release profile after storage for 3 months.
Collapse
|
21
|
El’tsova NO, Golubitskii GB, Budko EV. Analytical methods for studying the stability of pharmaceutical compositions and the compatibility of their components. JOURNAL OF ANALYTICAL CHEMISTRY 2014. [DOI: 10.1134/s1061934814100062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
22
|
Fan Y, Yang M, Wang Y, Li Y, Zhou Y, Chen X, Shan L, Wei J, Gao C. Preformulation characterization andin vivoabsorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery. Drug Dev Ind Pharm 2014; 41:801-11. [DOI: 10.3109/03639045.2014.903494] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
23
|
Chidambaram M, Krishnasamy K. Drug-Drug/Drug-Excipient Compatibility Studies on Curcumin using Non-Thermal Methods. Adv Pharm Bull 2014; 4:309-12. [PMID: 24754017 DOI: 10.5681/apb.2014.045] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2013] [Revised: 01/16/2014] [Accepted: 01/16/2014] [Indexed: 11/17/2022] Open
Abstract
PURPOSE Curcumin is a hydrophobic polyphenol isolated from dried rhizome of turmeric. Clinical usefulness of curcumin in the treatment of cancer is limited due to poor aqueous solubility, hydrolytic degradation, metabolism, and poor oral bioavailability. To overcome these limitations, we proposed to fabricate curcumin-piperine, curcumin-quercetin and curcumin-silibinin loaded polymeric nanoformulation. However, unfavourable combinations of drug-drug and drug-excipient may result in interaction and rises the safety concern. Hence, the present study was aimed to assess the interaction of curcumin with excipients used in nanoformulations. METHODS Isothermal stress testing method was used to assess the compatibility of drug-drug/drug-excipient. RESULTS The combination of curcumin-piperine, curcumin-quercetin, curcumin-silibinin and the combination of other excipients with curcumin, piperine, quercetin and silibinin have not shown any significant physical and chemical instability. CONCLUSION The study concludes that the curcumin, piperine, quercetin and silibinin is compatible with each other and with other excipients.
Collapse
Affiliation(s)
- Moorthi Chidambaram
- Department of Pharmacy, Annamalai University, Chidambaram, Tamil Nadu, India
| | | |
Collapse
|
24
|
Chadha R, Bhandari S. Drug–excipient compatibility screening—Role of thermoanalytical and spectroscopic techniques. J Pharm Biomed Anal 2014; 87:82-97. [DOI: 10.1016/j.jpba.2013.06.016] [Citation(s) in RCA: 136] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2013] [Revised: 06/05/2013] [Accepted: 06/09/2013] [Indexed: 11/29/2022]
|
25
|
Júlio TA, Zâmara IF, Garcia JS, Trevisan MG. Compatibility and stability of valsartan in a solid pharmaceutical formulation. BRAZ J PHARM SCI 2013. [DOI: 10.1590/s1984-82502013000400003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Valsartan (VAL) is a highly selective blocker of the angiotensin II receptor that has been widely used in the treatment of hypertension. Active pharmaceutical ingredient compatibility with excipients (crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose and titanium dioxide) is usually evaluated in solid pharmaceutical development. Compatibility and stability can be evaluated by liquid chromatography. Studies were performed using binary mixtures of 1:1 (w/w) VAL/excipient; samples were stored under accelerated stability test conditions (40 ºC at 75% relative humidity). The results indicate that VAL is incompatible with crospovidone and hypromellose, which reduced the VAL content and gave rise to new peaks in the chromatogram due to degradation products.
Collapse
|
26
|
Fuliaş A, Ledeţi I, Vlase G, Popoiu C, Hegheş A, Bilanin M, Vlase T, Gheorgheosu D, Craina M, Ardelean S, Ferechide D, Mărginean O, Moş L. Thermal behaviour of procaine and benzocaine Part II: compatibility study with some pharmaceutical excipients used in solid dosage forms. Chem Cent J 2013; 7:140. [PMID: 23962059 PMCID: PMC4015284 DOI: 10.1186/1752-153x-7-140] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2013] [Accepted: 08/15/2013] [Indexed: 11/12/2022] Open
Abstract
Background The compatibility study of active substances with excipients finds an important role in the domain of pharmaceutical research, being known the fact that final formulation is the one administered to the patient. In order to evaluate the compatibility between active substance and excipients, different analytical techniques can be used, based on their accuracy, reproducibility and fastness. Results Compatibility study of two well-known active substances, procaine and benzocaine, with four commonly used excipients, was carried out employing thermal analysis (TG/DTG/HF) and Fourier Transform Infrared Spectroscopy (UATR-FT-IR). The selected excipients were microcrystalline cellulose, lactose monohydrate, magnesium stearate and talc. Equal proportion of active substance and excipients (w/w) was utilized in the interaction study. The absolute value of the difference between the melting point peak of active substances and the one corresponding for the active substances in the analysed mixture, as well the absolute value of the difference between the enthalpy of the pure active ingredient melting peak and that of its melting peak in the different analysed mixtures were chosen as indexes of the drug-excipient interaction degree. All the results obtained through thermal analysis were also sustained by FT-IR spectroscopy. Conclusions The corroboration of data obtained by thermal analysis with the ones from FT-IR spectroscopy indicated that no interaction occurs between procaine and benzocaine, with microcrystalline cellulose and talc, as well for the benzocaine-lactose mixture. Interactions were confirmed between procaine and benzocaine respectively and magnesium stearate, and for procaine and lactose.
Collapse
Affiliation(s)
| | | | | | - Călin Popoiu
- Faculty of Pharmacy, University of Medicine and Pharmacy "Victor Babeş", Eftimie Murgu Square 2, Timişoara RO-300041, România.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Vueba ML, Batista de Carvalho LAE, Veiga F, Sousa JJ, Pina ME. In vitrorelease of ketoprofen from hydrophilic matrix tablets containing cellulose polymer mixtures. Drug Dev Ind Pharm 2012; 39:1651-62. [DOI: 10.3109/03639045.2012.729146] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
28
|
Kapil R, Dhawan S, Beg S, Singh B. Buccoadhesive films for once-a-day administration of rivastigmine: systematic formulation development and pharmacokinetic evaluation. Drug Dev Ind Pharm 2012; 39:466-80. [DOI: 10.3109/03639045.2012.665926] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|